Federal Register / Vol. 60, No. 51 / Thursday, March 16, 1995 / Notices 14291

of drafts of regulations or guidelines or

similar preexisting internal agency

documents, but only if their premature

disclosure is likely to significantly

frustrate implementation of proposed

agency action; review of trade secrets

and confidential commercial or

financial information submitted to the

agency; consideration of matters

involving investigatory files compiled

for law enforcement purposes; and

review of matters, such as personnel

records or individual patient records,

where disclosure would constitute a

clearly unwarranted invasion of

personal privacy.

Examples of portions of FDA advisory

committee meetings that ordinarily shall

not be closed include the review,

discussion, and evaluation of general

preclinical and clinical test protocols

and procedures for a class of drugs or

devices; consideration of labeling

requirements for a class of marketed

drugs or devices; review of data and

information on specific investigational

or marketed drugs and devices that have

previously been made public;

presentation of any other data or

information that is not exempt from

public disclosure pursuant to the FACA,

as amended; and, deliberation to

formulate advice and recommendations

to the agency on matters that do not

independently justify closing.

This notice is issued under section

10(a)(1) and (2) of the Federal Advisory

Committee Act (5 U.S.C. app. 2), and

FDA’s regulations (21 CFR part 14) on

advisory committees.

Dated: March 9, 1995.

Linda A. Suydam,

Interim Deputy Commissioner for Operations.

[FR Doc. 95–6427 Filed 3-15–95; 8:45 am]

BILLING CODE 4160–01–F

Office of the Secretary

Correction of Notice of Findings of

Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Correction.

SUMMARY: A Notice beginning on page

10588 in the issue of February 27, 1995,

entitled ‘‘Findings of Scientific

Misconduct’’ is hereby reprinted in its

entirety because of an omission in the

original printing:

Vivian N. Tanner, Cleveland Clinic

Foundation: The Division of Research

Investigations of the Office of Research

Integrity (ORI) conducted an

investigation into possible scientific

misconduct on the part of Vivian N.

Tanner while she was a clinic

coordinator for the Collaborative Ocular

Melanoma Study (COMS) at the

Cleveland Clinic Foundation (CCF). ORI

concluded that Ms. Tanner committed

scientific misconduct by falsifying and

fabricating clinical trial data on research

data forms related to a multicenter study

on the treatment of choroidal

melanoma, a rare form of eye cancer.

Due to these falsifications and

fabrications, inaccurate clinical data

were entered into the clinical trial

database. These acts were committed

over a period of several years, were

material, and, therefore, were

potentially detrimental to the study. The

CCF COMS project has received U.S.

Public Health Service support from

1985 to the present through subcontract

funds from a National Eye Institute

cooperative agreement award to the

COMS Coordinating Center, The Wilmer

Ophthalmological Institute, The Johns

Hopkins Medical Institutions,

Baltimore, Maryland. Ms. Tanner has

been debarred from eligibility for and

involvement in grants as well as other

assistance awards and contracts from

the Federal Government for a period of

three years. Because the COMS is an

ongoing study, no publications were

affected by the falsified or fabricated

data, and no clinical treatment has been

based on the results of the study.

FOR FURTHER INFORMATION, CONTACT:

Director, Division of Research

Investigations, Office of Research

Integrity, 301–443–5330.

Lyle W. Bivens, Ph.D.,

Director, Office of Research Integrity.

[FR Doc. 95–6446 Filed 3–15–95; 8:45 am]

BILLING CODE 4160–17–P

National Institutes of Health

Division of Research Grants; Notice of

Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Division

of Research Grants Special Emphasis

Panel (SEP) meetings:

Purpose/Agenda: To review individual

grant applications.

Name of SEP: Chemistry and Related

Sciences.

Date: March 27, 1995.

Time: 2:00 p.m.

Place: NIH, Westwood Building, Room

320, Telephone Conference.

Contact Person: Dr. Zakir Bengali,

Scientific Review Administrator, 5333

Westbard Ave., Room 320, Bethesda, MD

20892, (301) 594–7317.

Name of SEP: Microbiological and

Immunological Sciences.

Date: April 3, 1995.

Time: 10:00 a.m.

Place: NIH, Westwood Building, Room

407B, Telephone Conference.

Contact Person: Dr. Betty Hayden,

Scientific Review Administrator, 5333

Westbard Ave., Room 407B, Bethesda, MD

20892, (301) 594–7310.

Name of SEP: Microbiological and

Immunological Sciences.

Date: April 3, 1995.

Time: 3:00 p.m.

Place: NIH, Westwood Building, Room

407B, Telephone Conference.

Contact Person: Dr. Betty Hayden,

Scientific Review Administrator, 5333

Westbard Ave., Room 407B, Bethesda, MD

20892, (301) 594–7310.

Name of SEP: Behavioral and

Neurosciences.

Date: April 3, 1995.

Time: 8:30 a.m.

Place: Holiday Inn, Chevy Chase, MD.

Contact Person: Dr. Teresa Levitin,

Scientific Review Admin., 5333 Westbard

Ave., Room 303, Bethesda, MD 20894, (301)

594–7141.

Name of SEP: Chemistry and Related

Sciences.

Date: April 4, 1995.

Time: 1:00 p.m.

Place: NIH, Westwood Building, Room

435, Telephone Conference.

Contact Person: Dr. Marcelina Powers,

Scientific Review Administrator, 5333

Westbard Ave., Room 435, Bethesda, MD

20892, (301) 594–7120.

Name of SEP: Microbiological and

Immunological Sciences.

Date: April 4, 1995.

Time: 3:00 p.m.

Place: NIH, Westwood Building, Room

407B, Telephone Conference.

Contact Person: Dr. Betty Hayden,

Scientific Review Administrator, 5333

Westbard Ave., Room 407B, Bethesda, MD

20892, (301) 594–7310.

Name of SEP: Chemistry and Related

Sciences.

Date: April 6, 1995.

Time: 1:30 p.m.

Place: NIH, Westwood Building, Room

339B, Telephone Conference.

Contact Person: Dr. Jerry Critz, Scientific

Review Administrator, 5333 Westbard Ave.,

Room 339B, Bethesda, MD 20892, (301) 594–

7322.

Name of SEP: Microbiological and

Immunological Sciences.

Date: April 7, 1995.

Time: 1:00 p.m.

Place: NIH, Westwood Building, Room

403C, Telephone Conference.

Contact Person: Dr. Anita Weinblatt,

Scientific Review Admin., 5333 Westbard

Ave., Room 403C, Bethesda, MD 20892, (301)

594–7175.

Name of SEP: Chemistry and Related

Sciences.

Date: April 12, 1995.

Time: 1:00 p.m.

Place: NIH, Westwood Building, Room

435, Telephone Conference.

Contact Person: Dr. Marcelina Powers,

Scientific Review Administrator, 5333

Westbard Ave., Room 435, Bethesda, MD

20892, (301) 594–7120.
14292 Federal Register / Vol. 60, No. 51 / Thursday, March 16, 1995 / Notices

Name of SEP: Clinical Sciences.

Date: May 2, 1995.

Time: 2:30 p.m.

Place: NIH, Westwood Building, Room

439, Telephone Conference.

Contact Person: Dr. Gordon Johnson,

Scientific Review Admin., 5333 Westbard

Ave., Room 439, Bethesda, MD 20892, (301)

594–7216.

The meetings will be closed in accordance

with the provisions set forth in secs. 552(c)(4)

and 552b(c)(6), Title 5, U.S.C. Applications

and/or proposals and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the grant review cycle.

(Catalog of Federal Domestic Assistance

Program Nos. 93.306, 93.333, 93.337, 93.939–

93.396, 93.837–93.844, 93.846–93.878,

93.892, 93.893, National Institutes of Health,

HHS)

Dated: March 9, 1995.

Margery G. Grubb,

Senior Committee Management Specialist,

NIH.

[FR Doc. 95–6399 Filed 3–15–95; 8:45 am]

BILLING CODE 4140–01–M

Division of Research Grants; Notice of

Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Division

of Research Grants Special Emphasis

Panel (SEP) meetings:

Purpose/Agenda: To review individual

grant applications.

Name of SEP: Behavioral and

Neurosciences.

Date: March 21, 1995.

Time: 2:00 p.m.

Place: NIH, Westwood Building, Room

319C, Telephone Conference.

Contact Person: Dr. Carl Banner, Scientific

Review Administrator, 5333 Westbard Ave.,

Room 319A, Bethesda, MD 20892, (301) 594–

7206.

Name of SEP: Behavioral and

Neurosciences.

Date: April 3, 1995.

Time: 2:00 p.m.

Place: NIH, Westwood Building, Room

319C, Telephone Conference.

Contact Person: Dr. Anita Sostek, Scientific

Review Administrator, 5333 Westbard Ave.,

Room 319C, Bethesda, MD 20892, (301) 594–

7358.

Name of SEP: Behavioral and

Neurosciences.

Date: April 20, 1995.

Time: 8:00 a.m.

Place: Bethesda Marriott, Bethesda, MD.

Contact Person: Dr. Leonard Jakubczak,

Scientific Review Admin., 5333 Westbard

Ave., Room 325C, Bethesda, MD 20892, (301)

594–7198.

Name of SEP: Clinical Sciences.

Date: April 6, 1995.

Time: 11:00 a.m.

Place: NIH, Westwood Building, Room

220, Telephone Conference.

Contact Person: Dr. Daniel McDonald,

Scientific Review Administrator, 5333

Westbard Ave., Room 220, Bethesda, MD

20892, (301) 594–7301.

Name of SEP: Clinical Sciences.

Date: April 6, 1995.

Time: 12:00 noon.

Place: NIH, Westwood Building, Room

220, Telephone Conference.

Contact Person: Dr. Daniel McDonald,

Scientific Review Administrator, 5333

Westbard Ave., Room 220, Bethesda, MD

20892, (301) 594–7301.

Name of SEP: Clinical Sciences.

Date: April 6, 1995.

Time: 1:00 p.m.

Place: NIH, Westwood Building, Room

220, Telephone Conference.

Contact Person: Dr. Daniel McDonald,

Scientific Review Administrator, 5333

Westbard Ave., Room 220, Bethesda, MD

20892, (301) 594–7301.

The meetings will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the grant review cycle.

(Catalog of Federal Domestic Assistance

Program Nos. 93.306, 93.333, 93.337, 93.393–

93.396, 93.837–93.844, 93.846–93.878,

93.892, 93.893, National Institutes of Health,

HHS)

Dated: March 13, 1995.

Margery G. Grubb,

Senior Committee Management Specialist,

NIH.

[FR Doc. 95–6564 Filed 3–15–95; 8:45 am]

BILLING CODE 4140–01–M

Notice of Meeting of the Alternative

Medicine Program Advisory Council

and its Subcommittees

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the meetings of the

Alternative Medicine Program Advisory

Council (AMPAC) and its

Subcommittees on March 20, 21 and 22,

1995 at the National Institutes of Health,

Building 31, 9000 Rockville Pike,

Bethesda, Maryland.

In accordance with the provisions set

forth in sec. 552b(c)(6), Title 5, U.S.C.,

the full Council will meet on March 20

in closed session in Conference Room 7,

from 8:30 am to 9:30 am to discuss

conflict of interest procedures, issues,

and questions relating to the operation

of the AMPAC and its Subcommittees.

These discussions could disclose

information of a personal nature where

disclosure would constitute a clearly

unwarranted invasion of personal

privacy.

Meeting of the Subcommittees will be

open to the public on March 20 at the

times and locations listed below for the

discussion of planning and priority of

activities. Attendance by the public will

be limited to space available.

Subcommittee Name: Research

Subcommittee.

Place: Conference Room 6.

Time: 9:30 a.m. to 12:45 p.m.

Subcommittee Name: Information Services

Subcommittee.

Place: Conference Room 6.

Time: 1:45 p.m. to 5 p.m.

Subcommittee Name: Professional Liaison

Subcommittee.

Place: Conference Room 7.

Time: 1:45 p.m. to 5 p.m.

The full Council will meet in open session

on March 21 from 8:30 am to 5:15 pm and

on March 22 from 8:30 am to 12:30 pm in

Conference Room 10. There will be a report

from the Acting Director, Office of

Alternative Medicine, from the chairs of the

Research and Information Services

Subcommittees, and the Longrange Planning

Workgroup of the Strategic Planning

Subcommittee, and from representatives of

the two funded Centers for Alternative

Medicine Research. Comments may be made

by the public from 3:15 pm to 4:30 pm on

March 21 and from 10:45 am to 11:15 am on

March 22. Attendance by the public will be

limited to space available.

Ms. Beth Clay, Committee Management

Officer, Office of Alternative Medicine, NIH,

6120 Executive Boulevard, Suite 450,

Rockville, MD 20892–9904, phone (301) 402–

2467, fax (301) 402–4741, will furnish the

meeting agenda, roster of Council members,

and substantive program information upon

request. Any individual who requires special

assistance, such as sign language

interpretation or other reasonable

accommodations, should contact Ms. Clay at

the above location no later than March 16,

1995.

This notice is being published less than

fifteen days prior to the meeting due to

difficulties encountered in finalized the

agenda and the need to proceed with the

meeting as scheduled to address important

issues in a timely manner.

Dated: March 13, 1995.

Margery G. Grubb,

Senior Committee Management Specialist,

NIH.

[FR Doc. 95–6563 Filed 3–15–95; 8:45 am]

BILLING CODE 4140–01–M